| Literature DB >> 34173882 |
Mickaël Marloye1, Haider Inam2, Connor J Moore2, Vinciane Debaille3, Justin R Pritchard2, Michel Gelbcke1, Franck Meyer1, François Dufrasne1, Gilles Berger4,5.
Abstract
Ruthenium (Ru) and osmium (Os) complexes are of sustained interest in cancer research and may be alternative to platinum-based therapy. We detail here three new series of ruthenium and osmium complexes, supported by physico-chemical characterizations, including time-dependent density functional theory, a combined experimental and computational study on the aquation reactions and the nature of the metal-arene bond. Cytotoxic profiles were then evaluated on several cancer cell lines although with limited success. Further investigations were, however, performed on the most active series using a genetic approach based on RNA interference and highlighted a potential multi-target mechanism of action through topoisomerase II, mitotic spindle, HDAC and DNMT inhibition.Entities:
Keywords: Anticancer complex; Cell targeting; Metallodrug; Metal–arene; shRNA profiling
Year: 2021 PMID: 34173882 DOI: 10.1007/s00775-021-01873-9
Source DB: PubMed Journal: J Biol Inorg Chem ISSN: 0949-8257 Impact factor: 3.358